Tukysa OverviewTucatinib (INN), sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics). The recommended tucatinib dose is 300 mg taken orally twice a day in combination with trastuzumab (at standard dosage) and capecitabine (1000 mg...
Read more Tukysa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tucatinib
Recent Tukysa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 150mg, 50mg
NDC Database Records for Tukysa: (2 results)Sorted by National Drug Code
- 51144-001 Tukysa 50 mg Oral Tablet by Seattle Genetics, Inc.
- 51144-002 Tukysa 150 mg Oral Tablet by Seattle Genetics, Inc.